Prenetics Global Limited (PRE)
Market Closed
10 Aug, 20:00
NASDAQ (NMS) NASDAQ (NMS) Primary $
18. 80
+0.54
+2.9573%
$
313.83M Market Cap
1.08 P/E Ratio
- Div Yield
114,178 Volume
-2.4 Eps
$ 18.26
Previous Close Analysts:
Want to track PRE and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
PRE closed today higher at $18.8, an increase of 2.9573% from yesterday's close, completing a monthly decrease of -0.2653% or -$0.05. Over the past 12 months, PRE stock gained 17.6471%.
PRE is not paying dividends to its shareholders.
The last earnings report, released on Jun 11, 2026, exceeded the consensus estimates by 0.62%. On average, the company has surpassed earnings expectations by 0.3151%, based on the last three reports.
Prenetics Global Limited has completed 2 stock splits, with the recent split occurring on Nov 14, 2023.
The company's stock is traded on one exchange.
PRE Chart
People also search for
TESLA AND ALPHABET SHARES SLUMP IN PRE-MARKET TRADING
Alphabet shares pare back overnight as investors scrutinise its ever-increasing capex plans. Tesla is also down after missing on earnings while free cash flow turns negative.
Youtube | 2 weeks ago
All You Need to Know About Prenetics Global (PRE) Rating Upgrade to Buy
Prenetics Global (PRE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks | 7 months ago
What Makes Prenetics Global Limited (PRE) a Strong Momentum Stock: Buy Now?
Does Prenetics Global Limited (PRE) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks | 7 months ago
Prenetics Global Limited Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| BS Bill Sutherland Benchmark | 4,238.19 | $83,861.37 | $78,999.85 | -$4,861.52 | -5.8% |
Prenetics Global Limited (PRE) FAQ
What is the stock price today?
The current price is $18.80.
On which exchange is it traded?
Prenetics Global Limited is listed on NASDAQ (NMS).
What is its stock symbol?
The ticker symbol is PRE.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 313.83M.
Has Prenetics Global Limited ever had a stock split?
Prenetics Global Limited had 2 splits and the recent split was on Nov 14, 2023.
Prenetics Global Limited Profile
| Professional Services Industry | Industrials Sector | Sheng Wu Yeung CEO | NASDAQ (NMS) Exchange | G72245106 CUSIP |
| HK Country | 98 Employees | - Last Dividend | 14 Nov 2023 Last Split | 18 May 2022 IPO Date |
Overview
Prenetics Global Limited is a genomics-driven health sciences company, founded in 2007 with its headquarters based in Quarry Bay, Hong Kong. Specializing in the development of innovative genomics and health tech products, Prenetics aims to make personalized health care accessible. Through advanced genetic testing and digital health solutions, the company focuses on enhancing preventive health care and providing tailored treatment strategies.
Products and Services
- CircleDNA: A leading consumer genetic testing product that uses whole exome sequencing to provide a comprehensive DNA test. CircleDNA aims to uncover genetic predispositions to various health conditions and traits, offering users insights into their health and wellness.
- Circle HealthPod: A rapid detection health monitoring device designed for both professional and home use. It offers COVID-19 testing solutions, enabling quick and reliable results to help curb the spread of the virus.
- ColoClear: A non-invasive FIT-DNA colorectal cancer screening test. ColoClear is designed to detect early signs of colorectal cancer through a combination of fecal immunochemical testing and DNA analysis, promoting early intervention.
- Circle SnapShot: An off-the-shelf at-home blood test. This product provides a snapshot of the consumer's current health status, analyzing various biomarkers to give insights into health risks and conditions.
- ACTOnco: A comprehensive test that assists clinicians in choosing the optimal treatment for all major solid tumors. ACTOnco analyzes a wide range of cancer genes to provide targeted therapy options.
- ACTDrug+: A screening test that checks for 40 cancer genes to map drug options and provide treatment strategy options. ACTDrug+ is designed to facilitate personalized cancer treatment planning.
- ACTLung: A specialized test focused on biomarkers associated with lung cancer for targeted therapy. ACTLung aims to guide the treatment of lung cancer by identifying specific genetic alterations.
- ACTFusion: A genomic profiling service that decodes 13 fusion genes and more than 350 transcripts to map drug options. ACTFusion supports the development of personalized medicine by identifying key genetic drivers in cancers.
- ACTCerebra: A genomic profiling service for solid tumors, offering comprehensive insights into the genetic makeup of tumors to inform treatment strategies.
- ACTMonitor: This test analyzes 50 forms of circulating tumor DNA in the bloodstream, providing a non-invasive method to monitor tumor dynamics and treatment effectiveness.
- ACT Risk: A screening service that examines 67 cancer genes associated with 9 common hereditary cancers and 11 cancer syndromes. ACT Risk is aimed at identifying individuals at higher risk for developing cancer, facilitating early detection and preventive measures.
Contact Information
Address: Unit 701-706, K11 Atelier King’s Road
Phone: 852 2210 9588
Website: https://www.prenetics.com
